MedTrace Logo

Chart Review of Patients Undergoing Ketamine Treatments for Depression

NCT07099235 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-08-01

No results posted yet for this study

Summary

The Ontario Ketamine and Infusion Centre (OKIC) is a CPSO-certified Level-II OHP and an outpatient centre for intravenous ketamine treatments for treatment-resistant depression. This retrospective, observational study aims to conduct a chart review on patients receiving ketamine in a naturalistic setting to develop our understanding of ketamine as an interventional approach for treatment-resistant depression.

Conditions

  • Depression - Major Depressive Disorder

Interventions

DRUG

ketamine hydrochloride

Racemic ketamine is a 50/50 mixture of enantiomers (S)-ketamine and (R)-ketamine. The repeated administration of racemic ketamine intravenously at subanesthetic doses has emerged as an efficacious treatment for treatment-resistant depression.

Sponsors & Collaborators

  • Sunnybrook Health Sciences Centre

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2025-06-29
Completion
2025-06-29

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07099235 on ClinicalTrials.gov